Abstract:Ewing sarcoma is the second most common bone sarcoma in children after osteosarcoma. It is a very aggressive malignancy for which systemic treatment has greatly improved outcome for patients with localized disease, who now see survival rates of over 70%. However, for the quarter of patients presenting with metastatic disease, survival is still dismal with less than 30% of patients surviving past 5 years. Patients with disease relapse, local or distant, face an even poorer prognosis with an event-free 5-year survival rate of only 10%. Unfortunately, Ewing sarcoma patients have not yet seen the benefit of recent years’ technical achievements such as next-generation sequencing, which have enabled researchers to study biological systems at a level never seen before. In spite of large multinational studies, treatment of Ewing sarcoma relies entirely on chemotherapeutic agents that have been largely unchanged for decades. As many promising modern therapies, including monoclonal antibodies, small molecules, and immunotherapy, have been disappointing to date, there is no clear candidate as to which drug should be investigated in the next large-scale clinical trial. However, the mechanisms driving tumor development in Ewing sarcoma are slowly unfolding. New entities of Ewing-like tumors, with fusion transcripts that are related to the oncogenic EWSR1-FLI1 fusion seen in the majority of Ewing tumors, are being mapped. These tumors, although sharing much of the same morphologic features as classic Ewing sarcoma, behave differently and may require a different treatment. There are also controversies regarding local treatment of Ewing sarcoma. The radiosensitive nature of the disease and the tendency for Ewing sarcoma to arise in the axial skeleton make local treatment very challenging. Surgical treatment and radiotherapy have their pros and cons, which may give rise to different treatment strategies in different centers around the world. This review article discusses some of these controversies and reproduces the highlights from recent publications with regard to diagnostics, systemic treatment, and surgical treatment of Ewing sarcoma.

Pharmacotherapeutic strategies for epithelioid sarcoma: are we any closer to a non-surgical cure?

Translational Aspects of Epithelioid Sarcoma: Current Consensus

Shifting from a Biological-Agnostic Approach to a Molecular-Driven Strategy in Rare Cancers: Ewing Sarcoma Archetype

Novel Targeted Therapeutic Strategies for Ewing Sarcoma

Potential approaches to the treatment of Ewing's sarcoma

Ewing Sarcoma: Current Management and Future Approaches Through Collaboration

Role of immunotherapy in Ewing sarcoma

Ewing Sarcoma Meets Epigenetics, Immunology and Nanomedicine: Moving Forward into Novel Therapeutic Strategies

Unlocking epigenetics for precision treatment of Ewing's sarcoma

Emerging therapies in Ewing sarcoma

Ewing Sarcoma: Clinical State-of-the-Art

Targeting the EphA2 pathway: could it be the way for bone sarcomas?

Esophageal cancer: emerging therapeutics

A potential alternative systemic treatment option for epithelioid sarcoma

New strategies in soft tissue sarcoma treatment

Ewing Sarcoma—Diagnosis, Treatment, Clinical Challenges and Future Perspectives

The efficacy and safety of vincristine, irinotecan and anlotinib in Epithelioid Sarcoma

Current Status of Management and Outcome for Patients with Ewing Sarcoma

Long-term outcomes of sequential chemotherapy in epithelioid sarcoma

Prospects for Epigenetic Targeted Therapies of Bone and Soft-Tissue Sarcomas

Current and future therapeutic approaches for osteosarcoma